Analysts See $0.46 EPS for ONEOK, Inc. (OKE); 1 Analysts Are Bullish Raptor Pharmaceutical (RPTP) Last Week

October 13, 2017 - By Vivian Park

Analysts expect ONEOK, Inc. (NYSE:OKE) to report $0.46 EPS on November, 7.They anticipate $0.02 EPS change or 4.55% from last quarter’s $0.44 EPS. OKE’s profit would be $174.56M giving it 30.73 P/E if the $0.46 EPS is correct. After having $0.33 EPS previously, ONEOK, Inc.’s analysts see 39.39% EPS growth. About 1.59 million shares traded. ONEOK, Inc. (NYSE:OKE) has risen 23.81% since October 13, 2016 and is uptrending. It has outperformed by 7.11% the S&P500.

Among 5 analysts covering Raptor Pharmaceutical (NASDAQ:RPTP), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Raptor Pharmaceutical had 15 analyst reports since August 7, 2015 according to SRatingsIntel. Oppenheimer upgraded Raptor Pharmaceutical Corp (NASDAQ:RPTP) on Monday, September 28 to “Perform” rating. The firm has “Neutral” rating given on Tuesday, August 9 by Citigroup. FBR Capital maintained the stock with “Mkt Perform” rating in Monday, September 14 report. The rating was upgraded by Zacks to “Sell” on Wednesday, August 12. The firm has “Market Outperform” rating by JMP Securities given on Thursday, April 7. The rating was downgraded by Citigroup to “Neutral” on Tuesday, September 15. The firm has “Neutral” rating given on Friday, November 6 by Wedbush. FBR Capital initiated Raptor Pharmaceutical Corp (NASDAQ:RPTP) rating on Tuesday, August 11. FBR Capital has “Market Perform” rating and $16 target. The stock of Raptor Pharmaceutical Corp (NASDAQ:RPTP) has “Market Perform” rating given on Saturday, August 22 by FBR Capital. On Wednesday, January 27 the stock rating was upgraded by Citigroup to “Buy”. See Raptor Pharmaceutical Corp (NASDAQ:RPTP) latest ratings:

It closed at $9 lastly. It is down 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The company has market cap of $767.76 million. The Firm is focused on developing and commercializing transformative treatments for people affected by diseases. It currently has negative earnings. The Company’s product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Among 17 analysts covering ONEOK (NYSE:OKE), 4 have Buy rating, 0 Sell and 13 Hold. Therefore 24% are positive. ONEOK had 55 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of ONEOK, Inc. (NYSE:OKE) has “Outperform” rating given on Wednesday, July 5 by BMO Capital Markets. The firm earned “Buy” rating on Friday, June 17 by Citigroup. The rating was downgraded by Argus Research to “Hold” on Friday, June 17. The stock of ONEOK, Inc. (NYSE:OKE) has “Hold” rating given on Sunday, July 23 by RBC Capital Markets. The rating was upgraded by Credit Suisse on Thursday, February 2 to “Outperform”. Jefferies downgraded the shares of OKE in report on Thursday, January 12 to “Underperform” rating. As per Wednesday, January 25, the company rating was downgraded by Citigroup. Robert W. Baird maintained it with “Hold” rating and $54.0 target in Thursday, September 14 report. The firm earned “Overweight” rating on Wednesday, January 20 by Morgan Stanley. BMO Capital Markets maintained it with “Buy” rating and $59.0 target in Monday, September 25 report.

Investors sentiment increased to 1.35 in Q2 2017. Its up 0.04, from 1.31 in 2017Q1. It is positive, as 57 investors sold ONEOK, Inc. shares while 149 reduced holdings. 78 funds opened positions while 200 raised stakes. 188.94 million shares or 14.20% more from 165.44 million shares in 2017Q1 were reported. Hilltop Holdg accumulated 5,036 shares or 0.08% of the stock. Huntington State Bank invested 0% of its portfolio in ONEOK, Inc. (NYSE:OKE). Rice Hall James & Lc reported 0.01% in ONEOK, Inc. (NYSE:OKE). Art Advisors Lc has invested 0.57% of its portfolio in ONEOK, Inc. (NYSE:OKE). First Trust Lp owns 336,972 shares or 0.05% of their US portfolio. Lifeplan Fincl Gru Incorporated holds 0.2% or 5,735 shares in its portfolio. First Personal holds 0.01% in ONEOK, Inc. (NYSE:OKE) or 1,003 shares. Kbc Gru Nv invested in 0.1% or 199,670 shares. Ww Asset Inc invested 0.06% in ONEOK, Inc. (NYSE:OKE). Mu Invests Limited has 0.03% invested in ONEOK, Inc. (NYSE:OKE). Hartford Mngmt owns 213 shares. Suntrust Banks invested 0.01% in ONEOK, Inc. (NYSE:OKE). Mitsubishi Ufj Tru And Banking holds 0.05% in ONEOK, Inc. (NYSE:OKE) or 456,838 shares. Peak6 Limited Partnership has 0.01% invested in ONEOK, Inc. (NYSE:OKE) for 31,713 shares. Thompson Davis Company holds 229 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com